104 results on '"Eriksen, Erik Fink"'
Search Results
2. Intermittent dosing of zoledronic acid based on bone turnover marker assessment reduces vertebral and non-vertebral fractures.
3. Bisphosphonates as a treatment modality in osteoarthritis
4. Relationships Between Vitamin D Status and PTH over 5 Years After Roux-en-Y Gastric Bypass: a Longitudinal Cohort Study
5. Bone metabolism, bone mineral density and low-energy fractures 10 years after Roux-en-Y gastric bypass
6. Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS
7. Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG
8. High-sensitivity C-reactive protein is an independent risk factor for non-vertebral fractures in women and men: The Tromsø Study
9. Reduced Bone Material Strength is Associated with Increased Risk and Severity of Osteoporotic Fractures. An Impact Microindentation Study
10. Relationships of serum 25‐hydroxyvitamin D, ionized calcium and parathyroid hormone after obesity surgery
11. Disease-Modifying Adjunctive Therapy of Osteopenia and Osteoporosis with a Multimineral Marine Extract, LithoLexal ® Bone.
12. Bone Turnover in Relation to Thyroid-Stimulating Hormone in Hypothyroid Patients on Thyroid Hormone Substitution Therapy.
13. Excessive Decrease in Serum Magnesium After Total Thyroidectomy for Graves’ Disease Is Related to Development of Permanent Hypocalcemia
14. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis
15. Cellular mechanisms of bone remodeling
16. Thyroid Signaling Biomarkers in Female Symptomatic Hypothyroid Patients on Liothyronine versus Levothyroxine Monotherapy: A Randomized Crossover Trial.
17. Effects of anticatabolic and anabolic therapies at the tissue level
18. Zoledronic acid and clinical fractures and mortality after hip fracture
19. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
20. New developments in the treatment of osteoporosis
21. Vitamin D deficiency and aging: implications for general health and osteoporosis
22. Effect of Liothyronine Treatment on Quality of Life in Female Hypothyroid Patients With Residual Symptoms on Levothyroxine Therapy: A Randomized Crossover Study.
23. Disease-Modifying Adjunctive Therapy (DMAT) in Osteoarthritis--The Biological Effects of a Multi-Mineral Complex, LithoLexal® Joint--A Review.
24. Efficacy and Safety of a Once-Yearly Intravenous Zoledronic Acid 5 mg for Fracture Prevention in Elderly Postmenopausal Women with Osteoporosis Aged 75 and Older
25. Effect of Liothyronine Treatment on Dermal Temperature and Activation of Brown Adipose Tissue in Female Hypothyroid Patients: A Randomized Crossover Study.
26. Impact of osteonecrosis of the jaw on osteoporosis management: executive summary of an ESCEO and Foundation for Research on Osteoporosis and other Bone Diseases Working Group Meeting
27. The von Kossa reaction for calcium deposits: silver lactate staining increases sensitivity and reduces background
28. Polymorphisms in the transforming growth factor beta 1 gene and osteoporosis
29. Novel findings in gene expression detected in human osteosarcoma by cDNA microarray
30. Benmarkører ved behandling av osteoporose.
31. Changes in Bone Marrow Adipose Tissue One Year After Roux‐en‐Y Gastric Bypass: A Prospective Cohort Study.
32. Osteonecrosis after intranasal injection with bevacizumab in treating hereditary hemorrhagic telangiectasia: A case report.
33. Establishment of a tear protein biomarker panel differentiating between Graves’ disease with or without orbitopathy.
34. High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial.
35. Bone mineral density in patients with multiple sclerosis, hereditary ataxia or hereditary spastic paraplegia after at least 10 years of disease - a case control study.
36. Vitamin D og covid-19 -- kan vi trekke endelige konklusjoner?
37. Skeletal effects of a gastrin receptor antagonist in H+/K+ATPase beta subunit KO mice.
38. Commentary: Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics.
39. Østrogener i menopausen– på tide å endre anbefalingene?
40. Characteristics of Glucose Metabolism in Nordic and South Asian Subjects with Type 2 Diabetes.
41. Bone Turnover and Metabolism in Patients with Early Multiple Sclerosis and Prevalent Bone Mass Deficit: A Population-Based Case-Control Study.
42. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
43. Antifracture Efficacy and Reduction of Mortality in Relation to Timing of the First Dose of Zoledronic Acid After Hip Fracture.
44. Perspective: Remodeling and Vascular Spaces in Bone.
45. Teriparatide Increases Bone Formation in Modeling and Remodeling Osteons and Enhances IGF-II Immunoreactivity in Postmenopausal Women With Osteoporosis.
46. Differential Effects of Teriparatide and Alendronate on Bone Remodeling in Postmenopausal Women Assessed by Histomorphometric Parameters.
47. Polymorphisms in the Osteoprotegerin Gene Are Associated With Osteoporotic Fractures.
48. Cancellous Bone Remodeling Occurs in Specialized Compartments Lined by Cells Expressing Osteoblastic Markers.
49. A TA Repeat Polymorphism in the Estrogen Receptor Gene Is Associated with Osteoporotic Fractures but Polymorphisms in the First Exon and Intron Are Not.
50. Osteoporotic Fractures Are Associated with an 86-Base Pair Repeat Polymorphism in the Interleukin-1-Receptor Antagonist Gene But Not with Polymorphisms in the Interleukin-1β Gene.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.